Phase II study of gefitinib in patients with advanced salivary gland cancers.
Phase II study of gefitinib in patients with advanced salivary gland cancers.
复制标题
DOI：
10.1002/hed.23647
复制
发表时间：
2015-05
期刊：
影响因子：
--
通讯作者：
Blumenschein GR Jr
中科院分区：
文献类型：
--
作者：
Jakob JA;Kies MS;Glisson BS;Kupferman ME;Liu DD;Lee JJ;El-Naggar AK;Gonzalez-Angulo AM;Blumenschein GR Jr
确定表皮生长因子受体（EGFR）抑制剂吉非替尼在复发性/转移性涎腺癌患者中的抗肿瘤活性。腺样囊性（ACC）和非腺样囊性（非ACC）癌的II期研究。吉非替尼每日口服250 mg。主要终点为肿瘤缓解。次要终点包括无进展生存期（PFS）、总生存期（OS）和疾病控制率（DCR）。评估EGFR和HER 2表达并与结局相关。37例患者入组，36例可评价（18例ACC和18例非ACC）。未观察到任何反应。ACC和非ACC患者的中位PFS分别为4.3个月和2.1个月，中位OS分别为25.9个月和16个月。ACC患者8周时的DCR较高。未发生非预期毒性。EGFR和HER 2过表达与预后无关。我们没有观察到吉非替尼在晚期涎腺癌中的显著临床活性。NCT 00509002。
Determine the antitumor activity of the epidermal growth factor receptor (EGFR) inhibitor gefitinib in patients with recurrent/metastatic salivary gland cancer. Phase II study in adenoid cystic (ACC) and non-adenoid cystic (non-ACC) carcinomas. Gefitinib was administered 250mg orally daily. Primary endpoint was tumor response. Secondary endpoints included progression-free survival (PFS), overall survival (OS) and disease control rates (DCR). EGFR and HER2 expression were evaluated and correlated with outcomes. Thirty-seven patients were enrolled, and 36 were evaluable (18 with ACC and 18 with non-ACC). No responses were observed. Median PFS was 4.3 months and 2.1 months, and median OS was 25.9 months and 16 months for patients with ACC and non-ACC respectively. DCR at 8 weeks was higher in ACC patients. No unexpected toxicities occurred. EGFR and HER2 overexpression did not correlate with outcomes. We did not observe significant clinical activity of gefitinib in advanced salivary gland cancer. NCT00509002.
登录
查看更多内容
影响因子：
45.3
作者：
Agulnik, Mark;Cohen, Ezra W. E.;Siu, Lillian L.
通讯作者：
Siu, Lillian L.
DOI：
10.1002/hed.21052
发表时间：
2009-08-01
影响因子：
2.9
作者：
Vidal, Laura;Tsao, Ming S.;Siu, Lillian L.
通讯作者：
Siu, Lillian L.
影响因子：
50.5
作者：
Chau, N. G.;Hotte, S. J.;Siu, L. L.
通讯作者：
Siu, L. L.
影响因子：
4.8
作者：
Pfeffer, M. Raphael;Talmi, Yoav;Levitt, Mark
通讯作者：
Levitt, Mark
影响因子：
4.8
作者：
Locati, L. D.;Bossi, P.;Licitra, L.
通讯作者：
Licitra, L.